These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3994898)

  • 21. Faster clearance of sustained release verapamil in men versus women: continuing observations on sex-specific differences after oral administration of verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Schwartz JB
    Clin Pharmacol Ther; 2000 Sep; 68(3):286-92. PubMed ID: 11014410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Verapamil disposition kinetics in chronic atrial fibrillation.
    Kates RE; Keefe DL; Schwartz J; Harapat S; Kirsten EB; Harrison DC
    Clin Pharmacol Ther; 1981 Jul; 30(1):44-51. PubMed ID: 7237897
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of gender on the pharmacokinetics of verapamil and norverapamil in human.
    Dadashzadeh S; Javadian B; Sadeghian S
    Biopharm Drug Dispos; 2006 Oct; 27(7):329-34. PubMed ID: 16892180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of naringin on the pharmacokinetics of verapamil and one of its metabolites, norverapamil, in rabbits.
    Kim HJ; Choi JS
    Biopharm Drug Dispos; 2005 Oct; 26(7):295-300. PubMed ID: 16013069
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical pharmacokinetics of verapamil in patients with atrial fibrillation.
    Anderson P; BondessoN U; Sylvén C
    Eur J Clin Pharmacol; 1982; 23(1):49-57. PubMed ID: 7128672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Verapamil and norverapamil in plasma and breast milk during breast feeding.
    Anderson P; Bondesson U; Mattiasson I; Johansson BW
    Eur J Clin Pharmacol; 1987; 31(5):625-7. PubMed ID: 3830249
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasma level monitoring of D,L-verapamil and three of its metabolites by reversed-phase high-performance liquid chromatography.
    Köppel C; Wagemann A
    J Chromatogr; 1991 Sep; 570(1):229-34. PubMed ID: 1797832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Physiological disposition of verapamil in man.
    Schomerus M; Spiegelhalder B; Stieren B; Eichelbaum M
    Cardiovasc Res; 1976 Sep; 10(5):605-12. PubMed ID: 971476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of sustained-release verapamil after a single administration and at steady state.
    Mattila J; Mäntylä R; Taskinen J; Männistö P
    Eur J Drug Metab Pharmacokinet; 1985; 10(2):133-8. PubMed ID: 3840089
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil.
    Choi DH; Shin WG; Choi JS
    Eur J Clin Pharmacol; 2008 May; 64(5):445-9. PubMed ID: 18193210
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Verapamil and norverapamil determination in human plasma by gas-liquid chromatography using nitrogen-phosphorus detection: application to single-dose pharmacokinetic studies.
    Abernethy DR; Todd EL; Mitchell JR
    Pharmacology; 1984; 29(5):264-8. PubMed ID: 6494236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of the pharmacokinetics, pharmacodynamics, and dialyzability of verapamil in chronic hemodialysis patients.
    Hanyok JJ; Chow MS; Kluger J; Izard MW
    J Clin Pharmacol; 1988 Sep; 28(9):831-6. PubMed ID: 3230150
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of food, time of dosing, and body position on the pharmacokinetics and pharmacodynamics of verapamil and norverapamil.
    Gupta SK; Yih BM; Atkinson L; Longstreth J
    J Clin Pharmacol; 1995 Nov; 35(11):1083-93. PubMed ID: 8626882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
    McAllister RG; Kirsten EB
    Clin Pharmacol Ther; 1982 Apr; 31(4):418-26. PubMed ID: 7060323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effect of combined therapy on the pharmacokinetics and pharmacodynamics of verapamil and propranolol in patients with angina pectoris.
    McCourty JC; Silas JH; Tucker GT; Lennard MS
    Br J Clin Pharmacol; 1988 Mar; 25(3):349-57. PubMed ID: 3358897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
    Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
    Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of grapefruit juice and smoking on verapamil concentrations in steady state.
    Fuhr U; Müller-Peltzer H; Kern R; Lopez-Rojas P; Jünemann M; Harder S; Staib AH
    Eur J Clin Pharmacol; 2002 Apr; 58(1):45-53. PubMed ID: 11956673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differences in oral verapamil absorption as a function of time of day.
    Eldon MA; Battle MM; Voigtman RE; Colburn WA
    J Clin Pharmacol; 1989 Nov; 29(11):989-93. PubMed ID: 2600194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Verapamil kinetics during maintenance hemodialysis.
    Shah GM; Winer RL
    Am J Nephrol; 1985; 5(5):338-41. PubMed ID: 4061502
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the major metabolites of verapamil as substrates and inhibitors of P-glycoprotein.
    Pauli-Magnus C; von Richter O; Burk O; Ziegler A; Mettang T; Eichelbaum M; Fromm MF
    J Pharmacol Exp Ther; 2000 May; 293(2):376-82. PubMed ID: 10773005
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.